Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil McHugh

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Rheumatology (Oxford, England)|June 29, 2022
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprineJohn A Reynolds, Mary Gayed, Munther A Khamashta, et al.
Rheumatology Advances in Practice|August 22, 2019
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective studyGavin Clunie, Iain B McInnes, Nick Barkham, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next StepsWilliam Tillett, Neil McHugh, Ana-Maria Orbai, et al.
Current Rheumatology Reports|March 14, 2014
Patient involvement in outcome measures for psoriatic arthritisWilliam Tillett, Ade Adebajo, Mel Brooke, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus ErythematosusLucy M Carter, Adewonuola Alase, Zoe Wigston, et al.
Arthritis and Rheumatism|December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusChee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|February 26, 2010
Numerical scoring for the BILAG-2004 indexChee-Seng Yee, Lynne Cresswell, Vernon Farewell, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Nature Reviews. Rheumatology|November 9, 2023
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
Rheumatology (Oxford, England)|January 20, 2011
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patientsChee-Seng Yee, Vernon T Farewell, David A Isenberg, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Rheumatology (Oxford, England)|June 29, 2022
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprineJohn A Reynolds, Mary Gayed, Munther A Khamashta, et al.
Rheumatology Advances in Practice|August 22, 2019
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective studyGavin Clunie, Iain B McInnes, Nick Barkham, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next StepsWilliam Tillett, Neil McHugh, Ana-Maria Orbai, et al.
Current Rheumatology Reports|March 14, 2014
Patient involvement in outcome measures for psoriatic arthritisWilliam Tillett, Ade Adebajo, Mel Brooke, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus ErythematosusLucy M Carter, Adewonuola Alase, Zoe Wigston, et al.
Arthritis and Rheumatism|December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusChee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|February 26, 2010
Numerical scoring for the BILAG-2004 indexChee-Seng Yee, Lynne Cresswell, Vernon Farewell, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Nature Reviews. Rheumatology|November 9, 2023
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
Rheumatology (Oxford, England)|January 20, 2011
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patientsChee-Seng Yee, Vernon T Farewell, David A Isenberg, et al.
Pageof 14